News

Novartis will build a 35,000‑square‑foot radioligand therapy manufacturing facility in Winter Park, Florida, its fourth U.S. site in this...

Immunocore outlined a 2026 agenda centered on scaling Kimmtrak in metastatic uveal melanoma, advancing three registrational melanoma trials, and...

argenx reported unaudited 2025 global product net sales of approximately $4.15 billion, including $1.29 billion in the fourth quarter,...

ANI Pharmaceuticals has executed a board transition at a pivotal moment for its growth strategy. Patrick D. Walsh will...

Atsena Therapeutics has appointed McDavid Stilwell as chief financial officer as the company prepares to transition two inherited retinal...

Foghorn Therapeutics has secured a $50 million equity financing at a 30% premium to market and outlined 2026 objectives...

Teva has secured up to $500 million in development financing from Royalty Pharma to advance its anti–IL-15 monoclonal antibody,...

Immunocore laid out a 2026 agenda centered on expanding its melanoma franchise and advancing its TCR bispecific platform beyond...

Cellectis has set 2026 as a catalyst-heavy year, centering on a pivotal phase 2 trial for its off-the-shelf CAR-T,...

ImmuCell posted preliminary 2025 results and a strategic reset. Fourth-quarter sales reached $7.6 million, down 1.6% year over year,...